Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Vivotif Market Expansion From $ Billion In 2026 To $ Billion In 2030
The historic period’s expansion is explained by a higher prevalence of typhoid in endemic zones, a rise in international travel to regions with elevated risk, vaccination programs spearheaded by governments, the existence of oral vaccine options, and growing awareness of public health issues.
Several factors are fueling market expansion throughout the forecast period, such as increased funding for preventive healthcare, a growing need for travel-related vaccines, the extension of childhood immunization initiatives, a heightened focus on preventing antimicrobial resistance, and greater vaccine availability in emerging economies.
Download A Free Sample Report For Comprehensive Market Insights:
Vivotif Market Growth Drivers And Industry Catalysts
The growing prevalence of typhoid fever is anticipated to drive the expansion of the Vivotif market in the coming period. Typhoid fever is a bacterial illness caused by Salmonella Typhi, transmitted via contaminated food or water and characterized by symptoms such as fever, abdominal discomfort, and fatigue. This rise in typhoid fever cases stems from inadequate sanitation, limited access to clean water, and increasing antibiotic resistance, especially in low-income regions. Vivotif mitigates typhoid fever incidence by offering a preventive oral vaccine against Salmonella Typhi, particularly beneficial in areas with poor sanitation conditions. For example, in August 2024, data from GOV.UK, a UK government platform, revealed that approximately 645 typhoid fever cases were recorded in England, Wales, and Northern Ireland in 2023, up from 470 cases in 2022, reflecting a year-over-year increase in disease occurrence. Consequently, the rising incidence of typhoid fever is fueling the growth of the Vivotif market.
The increase in healthcare expenditure is projected to drive the Vivotif market forward in the future. Healthcare spending encompasses total outlays on health services and goods, covering medical care, hospital services, preventive measures, medications, research, infrastructure, and administrative costs aimed at enhancing or sustaining individual and population health. This spending growth results from an aging demographic, medical technology innovations, a higher prevalence of chronic diseases, and heightened demand for healthcare services. Such expenditure supports Vivotif by directing resources toward researching, producing, and distributing the oral typhoid vaccine, ensuring its availability and accessibility for populations vulnerable to typhoid fever, thereby aiding public health initiatives and disease prevention in high-incidence areas. In May 2024, the Office for National Statistics, a UK government agency, reported that healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared to a 0.9% increase in 2022, with UK healthcare expenditure reaching approximately $317.63 billion (£292 billion) in 2023. Thus, rising healthcare spending is propelling the Vivotif market’s growth.
Vivotif Market Segmentation And Category Breakdown
The vivotif market covered in this report is segmented –
1) By Clinical Indication: Typhoid, Other Indications
2) By Distribution Channel: Direct Sales, Online Pharmacies, Retail Pharmacies
3) By End-User: Adults, Pediatric
Vivotif Market Competitive Analysis Of Major Industry Participants
Major companies operating in the vivotif market are Bavarian Nordic A/S
Access The Complete Vivotif Market Report:
Vivotif Market Geographic Distribution And Regional Opportunities
Asia-Pacific was the largest region in the vivotif market in 2025. The regions covered in the vivotif market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model